Skip to content

Eton Pharmaceutical

US · ETON #2944 by market cap Listed 2018
54.88 +0.11 +0.20%
Live - 5344 symbols - heartbeat 58s ago · 2026-10-08 08:16
Pre-market 54.60 -0.51%
After-hours 55.10 +0.40%
Market cap
1.57B
P/B
33.67
EPS
-0.17
Reader sentiment Are you bullish or bearish on ETON?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Company notice
    4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
    SEC · 2026/7/8
  • Rating change
    CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/7/30
  • Company notice
    4/A: Eton Pharmaceutical | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner Opaleye Management Inc.
    SEC · 2026/7/18
  • H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/10/1
  • Rating change
    B. Riley Adjusts Price Target on Eton Pharmaceuticals to $70 From $40, Maintains Buy Rating
    MT Newswires · 2026/8/14
  • Eton Pharmaceutical(ETON.US) Officer Sells US$6.09 Million in Common Stock
    Market Newswire · 2026/8/21
  • Rating change
    H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/8/11
  • Rating change
    Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $62
    Market Newswire · 2026/7/28
  • Eton Pharmaceuticals (ETON) Gets a Buy From H.C. Wainwright
    TipRanks · 2026/10/1
  • Rating change
    H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/8/14
  • Rating change
    Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating
    Market Newswire · 2026/5/22
  • Company notice
    Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Gruber James R.
    SEC · 2026/1/15
  • Rating change
    B. Riley Securities Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/6/27
  • Rating change
    Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $62
    Market Newswire · 2026/8/13
  • Upgrade: Analysts Just Made A Notable Increase To Their Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Forecasts
    Simply Wall St · 2026/8/19
  • Rating change
    CCORF Initiates Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $60
    Market Newswire · 2026/7/17
  • Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (Miltefosine) Capsules
    GlobeNewswire · 2026/9/28
  • Company notice
    3: Eton Pharmaceutical | 3: Initial statement of beneficial ownership of securities- Matthews Judith M.
    SEC · 2026/6/2
  • Rating change
    Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $76
    Market Newswire · 2026/8/14
  • Company notice
    4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
    SEC · 2026/7/17

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:16:07 · For reference only, not investment advice and not tailored to your situation.